Elpis Biopharmaceuticals
PrivateLast Round
Series A
Oct 29, 2020
Total Funding Raised
$40M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Elpis Biopharmaceuticals is a biopharmaceutical company that develops next-generation multifunctional immunotherapies to transform cancer treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elpis Biopharmaceuticals Comparables
Compare Elpis Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| A2 Biotherapeutics | 81% | |
| ArsenalBio | 81% | |
| Mustang Bio Inc | 80% | |
Elpis Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 29, 2020 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased from 0 to 5, representing 45% of headcount.
- Jun 23, 2026
Monthly visitors increased 3342% MoM, reaching 15K.
Elpis Biopharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Elpis Biopharmaceuticals's valuation, stock price, and market status.